RhumbLine Advisers’s Design Therapeutics DSGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $163K | Buy |
48,317
+1,948
| +4% | +$6.56K | ﹤0.01% | 3337 |
|
|
2025
Q1 | $179K | Sell |
46,369
-6,563
| -12% | -$25.3K | ﹤0.01% | 3165 |
|
|
2024
Q4 | $327K | Buy |
52,932
+2,365
| +5% | +$14.6K | ﹤0.01% | 2943 |
|
|
2024
Q3 | $272K | Sell |
50,567
-2,500
| -5% | -$13.5K | ﹤0.01% | 3073 |
|
|
2024
Q2 | $178K | Buy |
53,067
+615
| +1% | +$2.06K | ﹤0.01% | 3292 |
|
|
2024
Q1 | $211K | Buy |
52,452
+1,588
| +3% | +$6.4K | ﹤0.01% | 3148 |
|
|
2023
Q4 | $135K | Sell |
50,864
-1,612
| -3% | -$4.27K | ﹤0.01% | 3351 |
|
|
2023
Q3 | $124K | Buy |
52,476
+886
| +2% | +$2.09K | ﹤0.01% | 3383 |
|
|
2023
Q2 | $325K | Sell |
51,590
-98
| -0.2% | -$617 | ﹤0.01% | 2954 |
|
|
2023
Q1 | $298K | Buy |
51,688
+72
| +0.1% | +$415 | ﹤0.01% | 2618 |
|
|
2022
Q4 | $530K | Sell |
51,616
-156
| -0.3% | -$1.6K | ﹤0.01% | 2437 |
|
|
2022
Q3 | $866K | Buy |
51,772
+3,544
| +7% | +$59.3K | ﹤0.01% | 2221 |
|
|
2022
Q2 | $675K | Buy |
48,228
+19,944
| +71% | +$279K | ﹤0.01% | 2335 |
|
|
2022
Q1 | $457K | Buy |
28,284
+4,995
| +21% | +$80.7K | ﹤0.01% | 2459 |
|
|
2021
Q4 | $499K | Buy |
23,289
+12,700
| +120% | +$272K | ﹤0.01% | 2510 |
|
|
2021
Q3 | $156K | Buy |
+10,589
| New | +$156K | ﹤0.01% | 2944 |
|